ABSTRACT
Home telemonitoring is becoming more important to home medical care for patients with heart failure. Since there are no data on home telemonitoring for Japanese patients with heart failure, we investigated its effect on cardiovascular outcomes. The HOMES-HF study was the first multicenter, open-label, randomized, controlled trial (RCT) to elucidate the effectiveness of home telemonitoring of physiological data, such as body weight, blood pressure, and pulse rate, for Japanese patients with heart failure (UMIN Clinical Trials Registry 000006839). The primary end-point was a composite of all-cause death or rehospitalization due to worsening heart failure. We analyzed 181 recently hospitalized patients with heart failure who were randomly assigned to a telemonitoring group (n = 90) or a usual care group (n = 91). The mean follow-up period was 15 (range 0-31) months. There was no statistically significant difference in the primary end-point between groups [hazard ratio (HR), 0.95; 95% confidence interval (CI), 0.548-1.648; p = 0.572]. Home telemonitoring for Japanese patients with heart failure was feasible; however, beneficial effects in addition to those of usual care were not demonstrated. Further investigation of more patients with severe heart failure, participation of home medical care providers, and use of a more integrated home telemonitoring system emphasizing communication as well as monitoring of symptoms and physiological data are required.
Subject(s)
Disease Management , Heart Failure/physiopathology , Hemodynamics/physiology , Home Care Services , Monitoring, Physiologic/methods , Telemedicine/methods , Aged , Female , Follow-Up Studies , Heart Failure/epidemiology , Humans , Japan/epidemiology , Male , Morbidity/trends , Prospective StudiesSubject(s)
Empyema, Tuberculous/complications , Inflammation/complications , Lymphoma, Follicular/etiology , Lymphoma, Large B-Cell, Diffuse/etiology , Pleural Neoplasms/etiology , Thyroid Neoplasms/etiology , Thyroiditis, Autoimmune/complications , Aged , Chronic Disease , Combined Modality Therapy , Fatal Outcome , Humans , Lymphoma, Follicular/therapy , Lymphoma, Large B-Cell, Diffuse/therapy , Male , Pleural Neoplasms/therapy , Remission Induction , Thyroid Neoplasms/therapyABSTRACT
The HCN4 channel shows differential expression patterns during the embryonic development and hypertrophy of hearts. Briefly, HCN4 expression is maximally activated in embryonic hearts and quickly diminishes after birth. However, it is reactivated during cardiac hypertrophy. The sequence analysis of HCN4 gene revealed the presence of a conserved NRSE motif, which is known to bind the transcriptional factor neuron-restrictive silencing factor (NRSF). A promoter analysis of HCN4 with rat cardiac myocytes identified the region inducing a basal transcriptional activity. This region drove a high activity in embryonic myocytes, but not in neonatal myocytes treated with hypertrophic agents. After confirming that NRSF protein binds to the NRSE, HCN4 promoter activities modified by NRSE were evaluated. With wild-type NRSE, the promoter activity correlated well with the developmental and hypertrophic changes of HCN4 expression, whereas mutant NRSE constructs failed. We conclude that the NRSE-NRSF system was implicated in HCN4 expression in cardiac myocytes.